PRO 367

Drug Profile

PRO 367

Latest Information Update: 21 Aug 2007

Price : $50

At a glance

  • Originator Progenics Pharmaceuticals
  • Class Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 21 Aug 2007 Discontinued - Phase-I for HIV infections treatment in USA (unspecified route)
  • 29 Aug 2000 Phase-I clinical trials for HIV infections treatment in USA (Unknown route)
  • 22 Jul 1997 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top